Breast cancer is the most prevalent cancer in women that frequently spreads and recurs, thus leading to high mortality. Despite advances in surgery and treatment, standard of care still relies primarily on chemo- and radiation therapies aimed at killing the tumor cells. Evolutionary models predict that selective pressure imposed by these approaches causes survival of resistant clones that eventually re-activate the disease. Based on the central involvement of metabolic tumor cell alterations in cancer, this application follows the hypothesis that therapeutic normalization of tumor cell metabolism can halt breast cancer progression and prevent relapse. If successful, this approach would not eradicate all residual disease, but rather achieve and maintain a disease symptom-free state. In principle, treatment aimed at normalizing tumor cell metabolism would not impose selective pressure, and thus not favor penetration of escaping clones to drive recurrence. If successful, therapeutic metabolic reprogramming could become a critical component of breast cancer care and have revolutionary impact on overall outcome by reducing the mortality in breast cancer. Having identified a cause-and-effect relationship between aberrant tumor cell mitochondrial complex I function, oncogenic growth, and metastatic progression in breast cancer, this information translated into a new strategy, where normalization of the NAD+/NADH redox balance through treatment with NAD precursors led to inhibition of tumor growth and metastatic disease in xenograft models and interference with breast cancer progression in an oncogene driven transgenic model of spontaneous breast cancer. Based on these findings, the proposed study seeks to 1. Evaluate the efficacy of NAD precursor treatment in xenograft and transgenic mouse models of breast cancer progression, including combination with standard of care;2. Employ targeted metabolomics to define the tumor cell NAD+/NADH metabolome in defined stages of disease advancement and treatment using ESI QQQ and NIMS technology, combined with XCMS metabolomic bioinformatics;and 3. Generate untargeted comprehensive metabolic profiles of progressive stages in breast cancer. The outcome from our study may identify therapeutic normalization of tumor cell metabolism, e.g. through NAD precursor treatment, as an effective, non-toxic way to silence breast cancer and prevent recurrence. The metabolome of breast cancer progression will empower the field and enable development of preventive approaches based on the concept of metabolic normalization. Interactive and collaborative efforts using the information generated will help to reduce the mortality in breast cancer patients.

Public Health Relevance

This project addresses NCIs provocative question PQ21: Given the appearance of resistance in response to cell killing therapies, can we extend survival by using approaches that keep tumors static? Despite improvements in breast cancer surgery and treatment, the mortality of breast cancer patients has largely remained unchanged. A major underlying problem is that the disease frequently recurs, often years after initial adjuvant therapy was apparently successful. At present, the standard of care relies primarily on chemo- and radiation therapies aimed at eradicating rapidly dividing tumor cells. However these treatments are very likely to select more aggressive tumor cells that eventually re-activate the disease and are treatment resistant. Dormant or slowly dividing tumor cells with stem-like characteristics could also remain unaffected and lead to recurrence. We hypothesize that breast cancer cells, regardless of the initial transforming event and disease driving mechanism, rely on altered metabolic circuitry that allows the tumor cells to meet their energy needs not only for accelerated growth, but also for survival under changing access to nutrients and oxygen within niches of the tumor microenvironment. Based on our result and the central involvement of metabolic tumor cell alterations in disease progression, we predict that therapeutic normalization of the tumor cell metabolism can halt breast cancer progression and prevent relapse. If successful, this approach would not eradicate all residual disease, but rather achieve and maintain a clinical disease symptom-free state. In principle, treatment aimed at normalizing tumor cell metabolism would not impose selective pressure and thus not favor penetration of escaping clones or cancer stem cells that could drive recurrence. Therefore, therapeutic metabolic reprogramming could become a critical component of breast cancer care and have revolutionary impact on overall outcome by reducing the mortality in breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA170737-02S1
Application #
8700569
Study Section
Special Emphasis Panel (ZCA1-SRLB-9 (M1))
Program Officer
Ogunbiyi, Peter
Project Start
2012-09-01
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
2
Fiscal Year
2013
Total Cost
$116,402
Indirect Cost
$54,976
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Weber, Martin R; Zuka, Masahiko; Lorger, Mihaela et al. (2016) Activated tumor cell integrin αvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream. Thromb Res 140 Suppl 1:S27-36
Paris, Liliana P; Johnson, Caroline H; Aguilar, Edith et al. (2016) Global metabolomics reveals metabolic dysregulation in ischemic retinopathy. Metabolomics 12:15
Johnson, Caroline H; Spilker, Mary E; Goetz, Laura et al. (2016) Metabolite and Microbiome Interplay in Cancer Immunotherapy. Cancer Res 76:6146-6152
Wold, Erik D; Smider, Vaughn V; Felding, Brunhilde H (2016) Antibody Therapeutics in Oncology. Immunotherapy (Los Angel) 2:
Kurczy, Michael E; Zhu, Zheng-Jiang; Ivanisevic, Julijana et al. (2015) Comprehensive bioimaging with fluorinated nanoparticles using breathable liquids. Nat Commun 6:5998
Johnson, Caroline H; Patti, Gary J; Courade, Jean-Philippe et al. (2015) Alterations in Spinal Cord Metabolism during Treatment of Neuropathic Pain. J Neuroimmune Pharmacol 10:396-401
Johnson, Caroline H; Ivanisevic, Julijana; Benton, H Paul et al. (2015) Bioinformatics: the next frontier of metabolomics. Anal Chem 87:147-56
Kurczy, Michael E; Ivanisevic, Julijana; Johnson, Caroline H et al. (2015) Determining conserved metabolic biomarkers from a million database queries. Bioinformatics 31:3721-4
Ivanisevic, Julijana; Siuzdak, Gary (2015) The Role of Metabolomics in Brain Metabolism Research. J Neuroimmune Pharmacol 10:391-5
Benton, H Paul; Ivanisevic, Julijana; Mahieu, Nathaniel G et al. (2015) Autonomous metabolomics for rapid metabolite identification in global profiling. Anal Chem 87:884-91

Showing the most recent 10 out of 28 publications